Unexpected Synergy Reveals New Therapeutic Strategy in SCLC

Publication date: Available online 8 April 2019Source: Trends in Pharmacological SciencesAuthor(s): Benjamin J. Drapkin, Anna F. FaragoDNA damage repair (DDR) inhibition and immune checkpoint blockade (ICB) have each individually shown modest clinical activity in small cell lung cancer (SCLC). Recently, Sen and colleagues (Cancer Discov. 2019;https://doi.org/10.1158/2159-8290.CD-18-1020) demonstrated that DDR inhibition can activate the stimulator of interferon genes (STING) innate immune pathway, providing strong rationale for combining DDR inhibition and ICB to treat SCLC.
Source: Trends in Pharmacological Sciences - Category: Drugs & Pharmacology Source Type: research